ArticleBrain and behavior2026
ASL/ALT Ratio in Familial and Sporadic Parkinson's Disease: Insights From Cross-Sectional Logistic Analysis.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) exhibits genetic heterogeneity with varying clinical presentations. The aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio has emerged as a potential indicator of neurodegenerative processes, yet its relationship with PD genetic subtypes remains unexplored.
objectiveThis study aims to investigate the relationship between the AST to ALT ratio (AST/ALT) and different genetic subtypes of PD.
methodsThis retrospective analysis included 1315 PD patients (1005 sporadic, 310 familial) from Parkinson's Progression Markers Initiative (PPMI) databases. Multivariable logistic regression models, restricted cubic splines, and inflection point analysis were employed to assess the relationship between the AST/ALT ratio and genetic subtypes of PD, adjusting for demographic, clinical, and biochemical covariates. Subgroup and sensitivity analyses were conducted to evaluate robustness, and a predictive model was developed using stepwise selection.
resultsCompared with sporadic PD (adjusted odds ratio [OR] 1.69, 95% confidence interval 1.19-2.39, p = 0.003). A nonlinear relationship was identified (nonlinearity p = 0.002), with an inflection point at 1.503. Above this threshold, the association became markedly stronger (OR 22.27, p = 0.0007), whereas no significant association was detected below it. Findings remained consistent across all subgroup and sensitivity analyses. A predictive model incorporating the AST/ALT ratio, along with clinical and demographic factors, achieved a moderate discriminatory ability (area under the curve 0.758).
conclusionsThe AST/ALT ratio demonstrates a significant, nonlinear association with genetic subtypes of PD, particularly among individuals with higher ratio values. This readily accessible serum marker may hold promise for refining PD subtyping and informing personalized management strategies, warranting validation in prospective and diverse cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.